FDA Investigator Shirshendu K Deb, PhD
Shirshendu K Deb, PhD has conducted inspections on 8 sites in 2 countries as of 26 Jul 2021. See below for a list of the FDA enforcement documents resulting from those inspections.
Investigator Details
Number of Inspected Sites:
8
Last Inspection Date:
26 Jul 2021
Investigator Role:
FDA Investigator
Redica ID:
Countries of Inspections:
United States of America,
India
FDA Investigators that have inspected at least one site in common with Shirshendu K Deb, PhD:
Ademola O Daramola,
Alan M Barker,
Alanna L Mussawwir Bias,
Alberto A Viciedo,
Alice S Tsao,
Alison N Stieg,
Amy S Graf,
Ana Paulap Sandee,
Andrew O Ejiofor,
Anthony F Lorenzo,
Arsen Karapetyan,
Art O Czabaniuk,
Atul J Agrawal,
Aurora Miha Trifanov,
Azza Talaat,
Barbara A Gullick,
Bei Y He,
Bijoy Panicker,
Brooke K Higgins,
Brooke K Seeman,
Carole L Jones,
Chaltu Nwakijra,
Chiang Syin, PhD,
Christian D Lynch (CDL),
Christina K Theodorou,
Colleen F Hoyt,
Cynthia Jim, CSO,
Daniel J Brown,
David A Oluwo,
Dawn C Olenjack,
Deborah M Trout,
Deyaa Shaheen,
Diane T Bargo,
Diane T O'brien,
Dipesh K Shah,
Douglas A Campbell,
Dr. Dominick Roselle,
Dr. Roslyn F Powers,
Dr. Yubing Tang,
Edmund F Mrak, Jr,
Edwin Melendez,
Emest F Bizjak,
Emilie E Kahn,
Emily J Orban,
Eric L Dong, BS,
Eric M Mueller, PharmD,
Erika V Butler,
Frederick F Razzaghi,
George Pyramides,
Guo Q Shen,
Gwyn G Dickinson,
Haitao Li,
Hector Jcolon Torres,
Jacob G Lutz,
Jacqueline Mdiaz Albertini,
James M Mason,
James M Simpson,
James R Evans,
Jason K Morgan,
Jeffery A Hangartner,
Jeffrey D Meng,
Jessica L Pressley,
Jogy George,
Jonah S Ufferfilge,
Jonathan W Chapman,
Joohi Castelvetere,
Joseph A Piechocki,
Joseph R Lambert,
Joseph T Madak,
Joseph W Matthews,
Junho Pak,
Karen C Daugherty,
Karen M Montgomery (KMM),
Kathleen B Swat,
Kathleen M Jordan,
Kellia N Hicks,
Kenneth M Gordon,
Kenneth Nieves,
Ko U Min,
Kristina L Conroy,
Larry K Austin,
Laureen F Kononen,
Lauren M Lilly, PhD,
Laurissa S Flowers,
Lawrence Harmon, Jr,
LCDR Anastasia M Piliafas Brown,
Lindsey Brown, PhD,
Lori S Lawless,
Marc S Neubauer,
Marcellinus D Dordunoo,
Marcus A Ray,
Margaret M Doherty,
Matthew M Henciak,
Matthew R Sleeter,
Melissa J Garcia,
Merideth K Rose,
Miah I Schneider,
Michael A Charles,
Michael Shanks, MS,
Michele L Forster, PhD,
Michele Perry Williams,
Mihaly S Ligmond,
Muralidhara B Gavini, PhD,
Nadeem I Chaudhry,
Nebil A Oumer,
Nerizza B Guerin,
Nicholas A Violand,
Nicole E Knowlton,
Omotunde O Osunsanmi,
Pankaj H Amin,
Patricia A Morrow,
Patsy J Domingo,
Prabhu P Raju,
Pratik S Upadhyay, DDC,
Rachael O Oyewole,
Rachel C Harrington,
Rebecca E Dombrowski,
Rebecca Rodriguez,
Robert H Wittorf,
Robert J Ham,
Robert J Martin,
Rose Ashley,
Salwa K Poole,
Samina S Khan,
Sanket N Patel,
Sarah E Rhoades,
Sarah M Meng,
Sarah M Napier,
Shafiq S Ahadi,
Shanna R Haden,
Sharon K Thoma, PharmD,
Sherry G Bous,
Shirley J Berryman,
Shusheen A Alexander,
Sidney B Priesmeyer,
Simone E Pitts,
Steven P Donald,
Susan M Jackson,
Suzanne M Healy,
Suzanne M Muchene,
Tajah L Blackburn,
Tara G Bizjak,
Tara L Breckenridge,
Tara L Greene,
Thomas E Friel,
Thuy T Nguyen, LCDR,
Tina M Pawlowski,
Tina S Roecklein,
Tonia F Bernard,
Toyin B Oladimeji,
Vipulchandra N Dholakia,
Viviana Matta,
Vivin George,
Walden H Lee,
Walter L Fava,
Wanda Y Honeyblue,
Wayne D Mcgrath,
William J Leonard,
Yaodong Huang,
Yvins Dezan,
Zhaoyang Meng,
Zhongren Wu
Shirshendu K Deb, PhD's Documents
| Publish Date | Document Type | Title |
|---|---|---|
| June, 2016 | EIR | Element Materials Technology Ann Arbor LLC - EIR, 2016-06-28 |
| September, 2021 | FDA 483 | Pharmaceutics International, Inc. - Form 483, 2021-09-29 |
| September, 2021 | EIR | Pharmaceutics International, Inc. - EIR, 2021-09-29 |
| September, 2021 | EIR | Pharmaceutics International, Inc. - EIR, 2021-09-29 |
| June, 2021 | FDA 483 | Bell-More Labs Inc - Form 483, 2021-06-07 |
| September, 2021 | FDA 483 | Pharmaceutics International, Inc. - Form 483, 2021-09-29 |
| April, 2019 | FDA 483 | ENDO USA, Inc. - Form 483, 2019-04-15 |
| April, 2019 | EIR | ENDO USA, Inc. - EIR, 2019-04-15 |
| March, 2020 | FDA 483 | Alembic Pharmaceuticals Limited - Form 483, 2020-03-13 |
| September, 2021 | FDA 483 Response | Pharmaceutics International, Inc. - Form 483R, 2021-11-18 |
| May, 2019 | FDA 483 | Nesher Pharmaceuticals (USA) LLC - Form 483, 2019-05-31 |
| April, 2019 | FDA 483 Response | ENDO USA, Inc. - Form 483R, 2019-05-02 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more